Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Monopar Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.78) for the quarter. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics' Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09.
A number of other research firms also recently commented on MNPR. HC Wainwright raised their price objective on Monopar Therapeutics from $6.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, November 11th. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $50.00 price target on the stock.
Read Our Latest Analysis on Monopar Therapeutics
Monopar Therapeutics Stock Performance
Shares of MNPR traded down $0.70 during trading hours on Thursday, hitting $24.46. The stock had a trading volume of 52,437 shares, compared to its average volume of 36,307. The company's fifty day simple moving average is $21.62 and its 200 day simple moving average is $10.55. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $38.50. The firm has a market cap of $129.10 million, a P/E ratio of -12.42 and a beta of 1.23.
Insider Buying and Selling at Monopar Therapeutics
In other news, CFO Karthik Radhakrishnan acquired 1,550 shares of the stock in a transaction on Monday, October 28th. The stock was bought at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares of the company's stock, valued at $25,187.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 34.90% of the stock is currently owned by corporate insiders.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
See Also
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
